National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011 (No. 9) (No. PB 57 of 2011) (Cth)
PB 57 of 2011
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011
(No.9)1
National Health Act 1953
I, FELICITY McNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.
Dated 29 August 2011
FELICITY McNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
1 Name of Instrument
(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011 (No. 9).
(2) This Instrument may also be cited as PB 57 of 2011.
2 Commencement
This Instrument commences on 1 September 2011.
3 Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010)
Schedule 1 and Schedule 2 amend the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010).
Schedule 1 Amendments relating to Medicare references
[1]Section 4, text of Note
omit: Medicare Australia CEO substitute: Chief Executive Medicare
[2]Paragraph 11(2)(a)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
[3]Paragraph 11(2)(b)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
[4]Paragraph 12(1)(a)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
[5]Paragraph 12(1)(b)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
[6]Paragraph 12(1)(c)
omit: Medicare Australia CEO (wherever occurring) substitute: Chief Executive Medicare
[7]Paragraph 12(1)(d)
omit: Medicare Australia CEO (twice occurring) substitute: Chief Executive Medicare
[8]Subsection 12(2)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
[9]Subsection 12(3)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Subsection 12(4)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Subsection 13(1)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Subparagraph 13(1)(b)(i)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Subsection 13(2)
omit: Medicare Australia CEO (twice occurring) substitute: Chief Executive Medicare
Subsection 13(3)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Subsection 13(4)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Paragraph 13(4)(a)
(a) omit: Medicare Australia CEO substitute: Chief Executive Medicare
(b) omit: CEO substitute: Chief Executive Medicare
Subsection 13(5)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Subsection 13(6)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Subsection 14(2)
omit: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe [Max Quantity 2; Number of Repeats 2]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761
(b) omit all codes from the column headed “Purposes” and substitute:
P2986 P2990 P2993 P3695 P3747 P3753 P3754
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe [Max Quantity 2; Number of Repeats 3]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761
(b) omit all codes from the column headed “Purposes” and substitute:
P3486 P3502 P3520 P3706 P3743 P3745 P3749 P3751
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe [Max Quantity 2; Number of Repeats 4]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761
(b) omit all codes from the column headed “Purposes” and substitute:
P3265 P3267 P3758 P3759
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe [Max Quantity 2; Number of Repeats 5]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761
(b) omit all codes from the column headed “Purposes” and substitute:
P2988 P2995 P3522 P3697 P3744 P3746 P3748 P3750 P3752 P3755 P3756 P3757 P3760 P3761
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen [Max Quantity 2; Number of Repeats 2]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761
(b) omit all codes from the column headed “Purposes” and substitute:
P2986 P2990 P2993 P3695 P3747 P3753 P3754
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen [Max Quantity 2; Number of Repeats 3]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761
(b) omit all codes from the column headed “Purposes” and substitute:
P3486 P3502 P3520 P3706 P3743 P3745 P3749 P3751
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen [Max Quantity 2; Number of Repeats 4]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C3750 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761
(b) omit all codes from the column headed “Purposes” and substitute:
P3265 P3267 P3758 P3759
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen [Max Quantity 2; Number of Repeats 5]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2986 C2988 C2990 C2993 C2995 C3265 C3267 C3486 C3502 C3520 C3522 C3695 C3697 C3706 C3743 C3744 C3745 C3746 C3747 C3748 C3749 C370 C3751 C3752 C3753 C3754 C3755 C3756 C3757 C3758 C3759 C3760 C3761
(b) omit all codes from the column headed “Purposes” and substitute:
P2988 P2995 P3522 P3697 P3744 P3746 P3748 P3750 P3752 P3755 P3756 P3757 P3760 P3761
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe, 6
omit all codes from the column headed “Circumstances” and substitute:
C2986 C2990 C2993 C3695 C3747 C3753 C3754
Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen, 6
omit all codes from the column headed “Circumstances” and substitute:
C2986 C2990 C2993 C3695 C3747 C3753 C3754
Schedule 1, entry for Bortezomib in the form Powder for injection 3.5 mg (with any determined brand of sodium chloride injection as the required solvent) [Max Quantity 4; Number of Repeats 2]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3762 C3763 C3764 C3765 C3766 C3767
(b) omit both codes from the column headed “Purposes” and substitute:
P3764 P3767
Schedule 1, entry for Bortezomib in the form Powder for injection 3.5 mg (with any determined brand of sodium chloride injection as the required solvent) [Max Quantity 4; Number of Repeats 3]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3762 C3763 C3764 C3765 C3766 C3767
(b) omit all codes from the column headed “Purposes” and substitute:
P3762 P3763 P3765 P3766
Schedule 1, entry for Certolizumab pegol
omit all codes from the column headed “Circumstances” and substitute:
C3476 C3714 C3768 C3769
Schedule 1, entry for Etanercept in the form Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL [Max Quantity 2; Number of Repeats 3]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3273 C3275 C3489 C3510 C3524 C3708 C3770 C3771 C3772 C3773 C3774 C3775 C3776 C3777 C3778 C3779 C3780 C3781
(b) omit all codes from the column headed “Purposes” and substitute:
P3273 P3275 P3489 P3510 P3524 P3708 P3770 P3772 P3774 P3776 P3778 P3779
Schedule 1, entry for Etanercept in the form Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL [Max Quantity 2; Number of Repeats 5]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3273 C3275 C3489 C3510 C3524 C3708 C3770 C3771 C3772 C3773 C3774 C3775 C3776 C3777 C3778 C3779 C3780 C3781
(b) omit all codes from the column headed “Purposes” and substitute:
P3771 P3773 P3775 P3777 P3780 P3781
Schedule 1, entry for Etanercept in the form Injections 50 mg in 1 mL single use pre-filled syringes, 4 [Max Quantity 1; Number of Repeats 3]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3273 C3275 C3489 C3510 C3524 C3708 C3770 C3771 C3772 C3773 C3774 C3775 C3776 C3777 C3778 C3779 C3780 C3781
(b) omit all codes from the column headed “Purposes” and substitute:
P3273 P3275 P3489 P3510 P3524 P3708 P3770 P3772 P3774 P3776 P3778 P3779
Schedule 1, entry for Etanercept in the form Injections 50 mg in 1 mL single use pre-filled syringes, 4 [Max Quantity 1;
Number of Repeats 5]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3273 C3275 C3489 C3510 C3524 C3708 C3770 C3771 C3772 C3773 C3774 C3775 C3776 C3777 C3778 C3779 C3780 C3781
(b) omit all codes from the column headed “Purposes” and substitute:
P3771 P3773 P3775 P3777 P3780 P3781
Schedule 1, entry for Etanercept in the form Injection 50 mg in 1 mL single use auto-injector, 4 [Max Quantity 1; Number of Repeats 3]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3273 C3275 C3489 C3510 C3524 C3708 C3770 C3771 C3772 C3773 C3774 C3775 C3776 C3777 C3778 C3779 C3780 C3781
(b) omit all codes from the column headed “Purposes” and substitute:
P3273 P3275 P3489 P3510 P3524 P3708 P3770 P3772 P3774 P3776 P3778 P3779
Schedule 1, entry for Etanercept in the form Injection 50 mg in 1 mL single use auto-injector, 4 [Max Quantity 1; Number of Repeats 5]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3273 C3275 C3489 C3510 C3524 C3708 C3770 C3771 C3772 C3773 C3774 C3775 C3776 C3777 C3778 C3779 C3780 C3781
(b) omit all codes from the column headed “Purposes” and substitute:
P3771 P3773 P3775 P3777 P3780 P3781
Schedule 1, entry for Golimumab in the form Injection 50 mg in 0.5 mL single use pre-filled syringe [Max Quantity 1;
Number of Repeats 3]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3484 C3495 C3497 C3516 C3518 C3718 C3782 C3783 C3784 C3785 C3786 C3787
(b) omit all codes from the column headed “Purposes” and substitute:
P3495 P3516 P3718 P3782 P3784 P3786
Schedule 1, entry for Golimumab in the form Injection 50 mg in 0.5 mL single use pre-filled syringe [Max Quantity 1;
Number of Repeats 5]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3484 C3495 C3497 C3516 C3518 C3718 C3782 C3783 C3784 C3785 C3786 C3787
(b) omit all codes from the column headed “Purposes” and substitute:
P3484 P3497 P3518 P3783 P3785 P3787
Schedule 1, entry for Golimumab in the form Injection 50 mg in 0.5 mL single use pre-filled pen [Max Quantity 1;
Number of Repeats 3]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3484 C3495 C3497 C3516 C3518 C3718 C3782 C3783 C3784 C3785 C3786 C3787
(b) omit all codes from the column headed “Purposes” and substitute:
P3495 P3516 P3718 P3782 P3784 P3786
Schedule 1, entry for Golimumab in the form Injection 50 mg in 0.5 mL single use pre-filled pen [Max Quantity 1;
Number of Repeats 5]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3484 C3495 C3497 C3516 C3518 C3718 C3782 C3783 C3784 C3785 C3786 C3787
(b) omit all codes from the column headed “Purposes” and substitute:
P3484 P3497 P3518 P3783 P3785 P3787
Schedule 1, entry for Ranibizumab
omit from the column headed “Circumstances”: C2822 substitute: C3788
Schedule 1, entry for Ustekinumab in the form Injection 45 mg in 0.5 mL [Max Quantity 1; Number of Repeats 1]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3248 C3250 C3789 C3790 C3791 C3792
(b) omit both codes from the column headed “Purposes” and substitute:
P3791 P3792
Schedule 1, entry for Ustekinumab in the form Injection 45 mg in 0.5 mL [Max Quantity 1; Number of Repeats 2]
(a) omit all codes from the column headed “Circumstances” and substitute:
C3248 C3250 C3789 C3790 C3791 C3792
(b) omit all codes from the column headed “Purposes” and substitute:
P3248 P3250 P3789 P3790
Schedule 1, entry for Verteporfin
omit all codes from the column headed “Circumstances” and substitute:
C3793 C3794 C3795
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C2987]
(a) omit from the column headed “Circumstances Code”: C2987 substitute: C3753
(b) omit from the column headed “Purposes Code”: P2987 substitute: P3753
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C2989]
(a) omit from the column headed “Circumstances Code”: C2989 substitute: C3755
(b) omit from the column headed “Purposes Code”: P2989 substitute: P3755
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C2991]
(a) omit from the column headed “Circumstances Code”: C2991 substitute: C3754
(b) omit from the column headed “Purposes Code”: P2991 substitute: P3754
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C2992]
(a) omit from the column headed “Circumstances Code”: C2992 substitute: C3756
(b) omit from the column headed “Purposes Code”: P2992 substitute: P3756
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C2994]
(a) omit from the column headed “Circumstances Code”: C2994 substitute: C3757
(b) omit from the column headed “Purposes Code”: P2994 substitute: P3757
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3266]
(a) omit from the column headed “Circumstances Code”: C3266 substitute: C3758
(b) omit from the column headed “Purposes Code”: P3266 substitute: P3758
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3268]
(a) omit from the column headed “Circumstances Code”: C3268 substitute: C3759
(b) omit from the column headed “Purposes Code”: P3268 substitute: P3759
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3270]
(a) omit from the column headed “Circumstances Code”: C3270 substitute: C3760
(b) omit from the column headed “Purposes Code”: P3270 substitute: P3760
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3272]
(a) omit from the column headed “Circumstances Code”: C3272 substitute: C3761
(b) omit from the column headed “Purposes Code”: P3272 substitute: P3761
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3487]
(a) omit from the column headed “Circumstances Code”: C3487 substitute: C3749
(b) omit from the column headed “Purposes Code”: P3487 substitute: P3749
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3488]
(a) omit from the column headed “Circumstances Code”: C3488 substitute: C3750
(b) omit from the column headed “Purposes Code”: P3488 substitute: P3750
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3503]
(a) omit from the column headed “Circumstances Code”: C3503 substitute: C3751
(b) omit from the column headed “Purposes Code”: P3503 substitute: P3751
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3504]
(a) omit from the column headed “Circumstances Code”: C3504 substitute: C3752
(b) omit from the column headed “Purposes Code”: P3504 substitute: P3752
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3521]
(a) omit from the column headed “Circumstances Code”: C3521 substitute: C3743
(b) omit from the column headed “Purposes Code”: P3521 substitute: P3743
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3523]
(a) omit from the column headed “Circumstances Code”: C3523 substitute: C3744
(b) omit from the column headed “Purposes Code”: P3523 substitute: P3744
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3570]
(a) omit from the column headed “Circumstances Code”: C3570 substitute: C3746
(b) omit from the column headed “Purposes Code”: P3570 substitute: P3746
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3696]
(a) omit from the column headed “Circumstances Code”: C3696 substitute: C3747
(b) omit from the column headed “Purposes Code”: P3696 substitute: P3747
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3698]
(a) omit from the column headed “Circumstances Code”: C3698 substitute: C3748
(b) omit from the column headed “Purposes Code”: P3698 substitute: P3748
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab [Circumstances Code C3707]
(a) omit from the column headed “Circumstances Code”: C3707 substitute: C3745
(b) omit from the column headed “Purposes Code”: P3707 substitute: P3745
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Adalimumab
display existing and re-numbered (amended) Circumstances and Purposes in numerical order
Schedule 4, Part 1, entry for Bortezomib [Circumstances Code C3196]
(a) omit from the column headed “Circumstances Code”: C3196 substitute: C3765
(b) omit from the column headed “Purposes Code”: P3196 substitute: P3765
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Bortezomib [Circumstances Code C3681]
(a) omit from the column headed “Circumstances Code”: C3681 substitute: C3766
(b) omit from the column headed “Purposes Code”: P3681 substitute: P3766
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Bortezomib [Circumstances Code C3682]
(a) omit from the column headed “Circumstances Code”: C3682 substitute: C3767
(b) omit from the column headed “Purposes Code”: P3682 substitute: P3767
(c) omit from the column headed “Circumstances and Purposes”, paragraph (g): authorization substitute: authorisation
(d) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Bortezomib [Circumstances Code C3683]
(a) omit from the column headed “Circumstances Code”: C3683 substitute: C3762
(b) omit from the column headed “Purposes Code”: P3683 substitute: P3762
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Bortezomib [Circumstances Code C3684]
(a) omit from the column headed “Circumstances Code”: C3684 substitute: C3763
(b) omit from the column headed “Purposes Code”: P3684 substitute: P3763
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Bortezomib [Circumstances Code C3685]
(a) omit from the column headed “Circumstances Code”: C3685 substitute: C3764
(b) omit from the column headed “Purposes Code”: P3685 substitute: P3764
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Bortezomib
display re-numbered (amended) Circumstances and Purposes in numerical order
Schedule 4, Part 1, entry for Certolizumab pegol [Circumstances Code C3564]
(a) omit from the column headed “Circumstances Code”: C3564 substitute: C3768
(b) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Certolizumab pegol [Circumstances Code C3715]
(a) omit from the column headed “Circumstances Code”: C3715 substitute: C3769
(b) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Certolizumab pegol
display existing and re-numbered (amended) Circumstances and Purposes in numerical order
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3274]
(a) omit from the column headed “Circumstances Code”: C3274 substitute: C3778
(b) omit from the column headed “Purposes Code”: P3274 substitute: P3778
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3276]
(a) omit from the column headed “Circumstances Code”: C3276 substitute: C3779
(b) omit from the column headed “Purposes Code”: P3276 substitute: P3779
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3277]
(a) omit from the column headed “Circumstances Code”: C3277 substitute: C3780
(b) omit from the column headed “Purposes Code”: P3277 substitute: P3780
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3278]
(a) omit from the column headed “Circumstances Code”: C3278 substitute: C3781
(b) omit from the column headed “Purposes Code”: P3278 substitute: P3781
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3490]
(a) omit from the column headed “Circumstances Code”: C3490 substitute: C3776
(b) omit from the column headed “Purposes Code”: P3490 substitute: P3776
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3491]
(a) omit from the column headed “Circumstances Code”: C3491 substitute: C3777
(b) omit from the column headed “Purposes Code”: P3491 substitute: P3777
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3511]
(a) omit from the column headed “Circumstances Code”: C3511 substitute: C3774
(b) omit from the column headed “Purposes Code”: P3511 substitute: P3774
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3512]
(a) omit from the column headed “Circumstances Code”: C3512 substitute: C3775
(b) omit from the column headed “Purposes Code”: P3512 substitute: P3775
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3525]
(a) omit from the column headed “Circumstances Code”: C3525 substitute: C3770
(b) omit from the column headed “Purposes Code”: P3525 substitute: P3770
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3526]
(a) omit from the column headed “Circumstances Code”: C3526 substitute: C3771
(b) omit from the column headed “Purposes Code”: P3526 substitute: P3771
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3567]
(a) omit from the column headed “Circumstances Code”: C3567 substitute: C3773
(b) omit from the column headed “Purposes Code”: P3567 substitute: P3773
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept [Circumstances Code C3709]
(a) omit from the column headed “Circumstances Code”: C3709 substitute: C3772
(b) omit from the column headed “Purposes Code”: P3709 substitute: P3772
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Etanercept
display existing and re-numbered (amended) Circumstances and Purposes in numerical order
Schedule 4, Part 1, entry for Golimumab [Circumstances Code C3496]
(a) omit from the column headed “Circumstances Code”: C3496 substitute: C3784
(b) omit from the column headed “Purposes Code”: P3496 substitute: P3784
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Golimumab [Circumstances Code C3498]
(a) omit from the column headed “Circumstances Code”: C3498 substitute: C3785
(b) omit from the column headed “Purposes Code”: P3498 substitute: P3785
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Golimumab [Circumstances Code C3517]
(a) omit from the column headed “Circumstances Code”: C3517 substitute: C3786
(b) omit from the column headed “Purposes Code”: P3517 substitute: P3786
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Golimumab [Circumstances Code C3519]
(a) omit from the column headed “Circumstances Code”: C3519 substitute: C3787
(b) omit from the column headed “Purposes Code”: P3519 substitute: P3787
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Golimumab [Circumstances Code C3578]
(a) omit from the column headed “Circumstances Code”: C3578 substitute: C3783
(b) omit from the column headed “Purposes Code”: P3578 substitute: P3783
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Golimumab [Circumstances Code C3719]
(a) omit from the column headed “Circumstances Code”: C3719 substitute: C3782
(b) omit from the column headed “Purposes Code”: P3719 substitute: P3782
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Golimumab
display existing and re-numbered (amended) Circumstances and Purposes in numerical order
Schedule 4, Part 1, entry for Ranibizumab [Circumstances Code C2822]
(a) omit from the column headed “Circumstances Code”: C2822 substitute: C3788
(b) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Ustekinumab [Circumstances Code C3249]
(a) omit from the column headed “Circumstances Code”: C3249 substitute: C3789
(b) omit from the column headed “Purposes Code”: P3249 substitute: P3789
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Ustekinumab [Circumstances Code C3251]
(a) omit from the column headed “Circumstances Code”: C3251 substitute: C3790
(b) omit from the column headed “Purposes Code”: P3251 substitute: P3790
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Ustekinumab [Circumstances Code C3253]
(a) omit from the column headed “Circumstances Code”: C3253 substitute: C3791
(b) omit from the column headed “Purposes Code”: P3253 substitute: P3791
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Ustekinumab [Circumstances Code C3255]
(a) omit from the column headed “Circumstances Code”: C3255 substitute: C3792
(b) omit from the column headed “Purposes Code”: P3255 substitute: P3792
(c) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Ustekinumab
display existing and re-numbered (amended) Circumstances and Purposes in numerical order
Schedule 4, Part 1, entry for Verteporfin [Circumstances Code C2683]
(a) omit from the column headed “Circumstances Code”: C2683 substitute: C3793
(b) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Verteporfin [Circumstances Code C2684]
(a) omit from the column headed “Circumstances Code”: C2684 substitute: C3794
(b) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO (twice occurring)
substitute: Chief Executive Medicare
Schedule 4, Part 1, entry for Verteporfin [Circumstances Code C2685]
(a) omit from the column headed “Circumstances Code”: C2685 substitute: C3795
(b) omit from the column headed “Circumstances and Purposes”: Medicare Australia CEO substitute: Chief Executive Medicare
Schedule 2 Amendments relating to PBS changes
[1]Schedule 1, omit entry for Amiloride
[2]Schedule 1, entry for Bromocriptine in the form Capsule 5 mg (as mesylate)
omit:
| Parlodel | NV | MP | C1001 C1255 C1841 C1842 C1843 C1844 | 60 | 5 |
[3]Schedule 1, entry for Bromocriptine in the form Capsule 10 mg (as mesylate)
omit:
| Parlodel | NV | MP | C1001 C1255 C1841 C1842 C1843 C1844 | 100 | 5 |
[4]Schedule 1, after entry for Buprenorphine with naloxone in the form Tablet (sublingual) 8 mg (as hydrochloride)-2 mg (as hydrochloride)
insert in the columns in the order indicated:
| Film (soluble) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride) | Sublingual | Suboxone Film 2/0.5 | RC | MP NP See Note 1 | See Note 3 | See Note 3 | See Note 3 | See Note 3 | D |
| Film (soluble) 8 mg (as hydrochloride)-2 mg (as hydrochloride) | Sublingual | Suboxone Film 8/2 | RC | MP NP See Note 1 | See Note 3 | See Note 3 | See Note 3 | See Note 3 | D |
[5]Schedule 1, entry for Calcipotriol
omit from the column headed “Responsible Person” (twice occurring): CS substitute: LO
[6]Schedule 1, entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g
omit from the column headed “Responsible Person”: CS substitute: LO
Schedule 1, after entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g
insert in the columns in the order indicated:
| Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g | Application | Daivobet 50/500 gel | LO | MP NP | C3827 | 1 | 1 |
[8]Schedule 1, entry for Cetuximab in the form Solution for I.V. infusion 100 mg in 20 mL [Max Quantity 1; Number of Repeats 0]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2713 C2714 C2715 C3843 C3844
(b) omit all codes from the column headed “Purposes” and substitute:
P2713 P2714 P3843 P3844
[9]Schedule 1, entry for Cetuximab in the form Solution for I.V. infusion 100 mg in 20 mL [Max Quantity 1; Number of Repeats 6]
omit all codes from the column headed “Circumstances” and substitute:
C2713 C2714 C2715 C3843 C3844
Schedule 1, entry for Cetuximab Solution for I.V. infusion 500 mg in 100 mL [Max Quantity 1; Number of Repeats 0]
(a) omit all codes from the column headed “Circumstances” and substitute:
C2713 C2714 C2715 C3843 C3844
(b) omit all codes from the column headed “Purposes” and substitute:
P2713 P2714 P3843 P3844
Schedule 1, entry for Cetuximab in the form Solution for I.V. infusion 500 mg in 100 mL [Max Quantity 1; Number of Repeats 6]
omit all codes from the column headed “Circumstances” and substitute:
C2713 C2714 C2715 C3843 C3844
Schedule 1, entry for Cimetidine
omit:
| Tablet 200 mg | Oral | Magicul 200 | AF | MP NP | 120 | 5 |
Schedule 1, entry for Ciprofloxacin in the form Eye drops 3 mg (as hydrochloride) per mL, 5 mL
substitute:
| Eye drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the eye | CiloQuin | IQ | MP | C1031 | 2 | 0 |
| AO | C3830 | 2 | 0 | ||||
| Ciloxan | AQ | MP | C1031 | 2 | 0 | ||
| AO | C3830 | 2 | 0 |
Schedule 1, after entry for Clopidogrel in the form Tablet 75 mg (as besilate) (Clovix 75)
insert in the columns in the order indicated:
| Tablet 75 mg | Oral | Clopidogrel-DRLA | RZ | MP NP | C1719 C1720 C1721 C1722 C1723 C1724 | 28 | 5 |
Schedule 1, omit entry for Clotrimazole
Schedule 1, entry for Dalteparin in each of the forms: Injection containing dalteparin sodium 2,500 I.U. (anti-Xa) in 0.2 mL single dose pre-filled syringe; and Injection containing dalteparin sodium 5,000 I.U. (anti-Xa) in 0.2 mL single dose pre-filled syringe
(a) omit from the column headed “Max Quantity”: 10 substitute: 20
(b) omit from the column headed “Number of Repeats”: 1 substitute: 0
Schedule 1, after entry for Dalteparin in the form Injection containing dalteparin sodium 10,000 I.U. (anti-Xa) in 1 mL single dose
pre-filled syringe
insert in the columns in the order indicated:
| Injection containing dalteparin sodium 12,500 I.U. (anti-Xa) in 0.5 mL single dose pre-filled syringe | Injection | Fragmin | PF | MP NP | 10 | 1 |
Schedule 1, entry for Deferasirox
omit all codes from the column headed “Circumstances” (all instances) and substitute:
C3828 C3829
Schedule 1, entry for Dexamethasone
omit:
| Eye drops 1 mg per mL, 5 mL | Application to the eye | Maxidex | AQ | MP NP | 1 | 2 |
substitute:
| Eye drops 1 mg per mL, 5 mL | Application to the eye | Maxidex | AQ | AO | 1 | 0 |
| MP NP | 1 | 2 |
Schedule 1, entry for Doxycycline in the form Tablet 100 mg (as hydrochloride)
(a) omit:
| Vibramycin | PF | PDP | 7 | 0 |
(b) omit:
| Vibramycin | PF | MP NP | 7 | 1 |
(c) omit:
| Vibramycin | PF | MP NP | P1459 | 21 | 0 |
(d) omit:
| Vibramycin | PF | MP NP | P1279 | 28 | 0 |
Schedule 1, after entry for Enoxaparin in the form Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe
insert in the columns in the order indicated:
| MP NP | P1148 | 20 | 3 |
Schedule 1, after entry for Enoxaparin in the form Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe
insert in the columns in the order indicated:
| MP NP | P1148 | 20 | 3 |
Schedule 1, entry for Escitalopram in each of the forms: Tablet 10 mg (as oxalate); and Tablet 20 mg (as oxalate)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| Escitalopram-DRLA | RZ | MP NP | C1211 | 28 | 5 |
Schedule 1, entry for Exemestane in the form Tablet 25 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| Exemestane Pfizer | FZ | MP NP | C1541 C2457 | 30 | 5 |
Schedule 1, after entry for Fentanyl in the form Lozenges 1600 micrograms (as citrate), 30
insert in the columns in the order indicated:
| Transdermal patch 1.28 mg | Transdermal | Denpax | AF | MP NP | C1062 | 5 | 0 |
| Transdermal patch 2.063 mg | Transdermal | Fenpatch 12 | ZP | MP NP | C1062 | 5 | 0 |
Schedule 1, after entry for Fentanyl in the form Transdermal patch 2.55 mg
insert in the columns in the order indicated:
| Transdermal patch 4.125 mg | Transdermal | Fenpatch 25 | ZP | MP NP | C1062 | 5 | 0 |
Schedule 1, after entry for Fentanyl in the form Transdermal patch 7.65 mg
insert in the columns in the order indicated:
| Transdermal patch 8.25 mg | Transdermal | Fenpatch 50 | ZP | MP NP | C1062 | 5 | 0 |
Schedule 1, after entry for Fentanyl in the form Transdermal patch 10.20 mg
insert in the columns in the order indicated:
| Transdermal patch 12.375 mg | Transdermal | Fenpatch 75 | ZP | MP NP | C1062 | 5 | 0 |
Schedule 1, after entry for Fentanyl in the form Transdermal patch 12.6 mg
insert in the columns in the order indicated:
| Transdermal patch 16.5 mg | Transdermal | Fenpatch 100 | ZP | MP NP | C1062 | 5 | 0 |
Schedule 1, after entry for Fentanyl in the form Transdermal patch 16.8 mg
insert in the columns in the order indicated:
| Ferrous fumarate | Tablet 200 mg (equivalent to 67.5 mg iron) | Oral | Ferro-tab | AE | MP NP | 60 | 1 |
Schedule 1, entry for Filgrastim in each of the forms Injection 120 micrograms in 0.2 mL single use pre-filled syringe (Nivestim); Injection 300 micrograms in 1 mL; Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Neupogen); Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim); Injection 480 micrograms in 1.6 mL; Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Neupogen); and Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)
insert in numerical order in the column headed “Circumstances”:
C3833 C3834
Schedule 1, after entry for Filgrastim in the form Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim)
insert:
| Fingolimod | Capsule 500 micrograms (as hydrochloride) | Oral | Gilenya | NV | MP | C3845 C3846 | 28 | 5 |
Schedule 1, after entry for Fluconazole in the form Capsule 200 mg (Ozole)
insert in the columns in the order indicated:
| Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | PF | MP NP | C3835 C3836 C3837 C3838 C3839 C3840 | 1 | 0 |
Schedule 1, entry for Flupenthixol Decanoate
insert as first item in the columns in the order indicated:
| Oily I.M. injection 20 mg in 1 mL | Injection | Fluanxol Depot | LU | MP NP | 5 | 0 |
Schedule 1, entry for Folinic acid
omit from the column headed “Authorised Prescriber” (all instances): NP
Schedule 1, entry for Gabapentin in the form Capsule 100 mg
omit:
| Gantin | AW | MP NP | C2664 | 100 | 5 |
Schedule 1, entry for Gentamicin
omit:
| Eye drops 3 mg (as sulfate) per mL, 5 mL | Application to the eye | Genoptic | AG | MP | C1188 C1391 C1714 | 1 | 2 |
substitute:
| Eye drops 3 mg (as sulfate) per mL, 5 mL | Application to the eye | Genoptic | AG | MP | C1188 C1391 C1714 | 1 | 2 |
| AO | C1391 C1714 | 1 | 2 |
Schedule 1, after entry for Glucose Indicator—Blood in the form Test strips, 50 (SensoCard)
insert in the columns in the order indicated:
| Test strips, 50 (TRUEbalance) | For external use | TRUEbalance | NX | MP NP | 2 | 5 |
| MP | P3035 | 2 | 11 | |||
| Test strips, 50 (TRUEresult) | For external use | TRUEresult | NX | MP NP | 2 | 5 |
| MP | P3035 | 2 | 11 |
Schedule 1, entry for Imatinib in the form Tablet 100 mg (as mesylate) [Max Quantity 60; Number of Repeats 2]
(a) omit from the column headed “Circumstances”:
C3232 C3451
(b) insert in numerical order in the column headed “Circumstances”:
C3847 C3848
C3849 C3850
(c) omit from the column headed “Purposes”:
P3232 P3451
(d) insert in numerical order in the column headed “Purposes”:
P3849 P3850
Schedule 1, entry for Imatinib in the form Tablet 100 mg (as mesylate) [Max Quantity 60; Number of Repeats 5]
(a) omit from the column headed “Circumstances”:
C3232 C3451
(b) insert in numerical order in the column headed “Circumstances”:
C3847 C3848
C3849 C3850
(c) insert in numerical order in the column headed “Purposes”:
P3847 P3848
Schedule 1, entry for Imatinib in the form Tablet 400 mg (as mesylate) [Max Quantity 30; Number of Repeats 2]
(a) omit from the column headed “Circumstances”:
C3232 C3451
(b) insert in numerical order in the column headed “Circumstances”:
C3847 C3848
C3849 C3850
(c) omit from the column headed “Purposes”:
P3232 P3451
(d) insert in numerical order in the column headed “Purposes”:
P3849 P3850
Schedule 1, entry for Imatinib in the form Tablet 400 mg (as mesylate) [Max Quantity 30; Number of Repeats 5]
(a) omit from the column headed “Circumstances”:
C3232 C3451
(b) insert in numerical order in the column headed “Circumstances”:
C3847 C3848
C3849 C3850
(c) insert in numerical order in the column headed “Purposes”:
P3847 P3848
Schedule 1, entry for Isosorbide Dinitrate
omit:
| Tablet 10 mg | Oral | Sorbidin | AF | MP NP | 200 | 2 |
Schedule 1, entry for Leflunomide in the form Tablet 10 mg [for the brands APO-Leflunomide; Lunava 10]
(a) omit from the column headed “Purposes”: 30 (leave column blank)
(b) omit from the column headed “Max Quantity”: 5 substitute: 30
(c) insert in the column headed “Number of Repeats”: 5
Schedule 1, entry for Leflunomide in the form Tablet 20 mg [for the brands APO-Leflunomide; Lunava 20]
(a) omit from the column headed “Purposes”: 30 (leave column blank)
(b) omit from the column headed “Max Quantity”: 5 substitute: 30
(c) insert in the column headed “Number of Repeats”: 5
Schedule 1, entry for Mesalazine in the form Suppository 1 g
omit from the column headed “Max Quantity”: 28 substitute: 30
Schedule 1, entry for Minocycline
omit:
| Capsule 100 mg (as hydrochloride) | Akamin 100 | AF | MP NP | 11 | 0 |
Schedule 1, omit entry for Neomycin
Schedule 1, after entry for Ofloxacin in the form Eye drops 3 mg per mL, 5 mL
insert in the columns in the order indicated:
| AO | C3830 | 2 | 0 |
Schedule 1, entry for Ondansetron in each of the forms: I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL; and I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| Ondansetron Alphapharm | AF | MP NP See Note 1 | C3050 C3611 See Note 2 | See Note 2 | 1 See Note 2 | 0 See Note 2 |
Schedule 1, entry for Pegfilgrastim in the form Injection 6 mg in 0.6 mL single use pre-filled syringe
insert in numerical order in the column headed “Circumstances”:
C3833 C3834
Schedule 1, entry for Perindopril in the form Tablet containing perindopril erbumine 2 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| Idaprex 2 | SZ | MP NP | 30 | 5 |
Schedule 1, entry for Perindopril in the form Tablet containing perindopril erbumine 4 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| Idaprex 4 | SZ | MP NP | 30 | 5 |
Schedule 1, entry for Perindopril in the form Tablet containing perindopril erbumine 8 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| Idaprex 8 | SZ | MP NP | 30 | 5 |
Schedule 1, entry for Perindopril with Indapamide in the form Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| Idaprex Combi 4/1.25 | SZ | MP NP | C3307 | 30 | 5 |
Schedule 1, entry for Pramipexole in the form Tablet (extended release) containing pramipexole hydrochloride 375 micrograms
omit from the column headed “Number of Repeats”: 0 substitute: 5
Schedule 1, entry for Prednisolone with Phenylephrine
substitute:
| Prednisolone with Phenylephrine | Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL | Application to the eye | Prednefrin Forte | AG | AO | C1465 | 1 | 0 |
| MP NP | C1077 C1465 | 1 | 2 |
Schedule 1, entry for Quinapril in each of the forms: Tablet 5 mg (as hydrochloride); Tablet 10 mg (as hydrochloride); and Tablet 20 mg (as hydrochloride)
omit from the column headed “Responsible Person”: AL substitute: FZ
Schedule 1, entry for Risperidone in each of the forms: I.M. injection (modified release), set containing 1 vial powder for injection 25 mg and 1 pre-filled syringe diluent 2 mL; I.M. injection (modified release), set containing 1 vial powder for injection 37.5 mg and 1 pre-filled syringe diluent 2 mL; and I.M. injection (modified release), set containing 1 vial powder for injection 50 mg and 1 pre-filled syringe diluent 2 mL
insert in numerical order in the column headed “Circumstances”:
C3841
Schedule 1, omit entry for Sulindac
Schedule 1, entry for Tobramycin
(a) omit:
| Eye drops 3 mg per mL, 5 mL | Application to the eye | Tobrex | AQ | MP | C1188 C1391 C1714 | 1 | 2 |
substitute:
| Eye drops 3 mg per mL, 5 mL | Application to the eye | Tobrex | AQ | MP | C1188 C1391 C1714 | 1 | 2 |
| AO | C1391 C1714 | 1 | 2 |
(b) omit:
| Eye ointment 3 mg per g, 3.5 g | Application to the eye | Tobrex | AQ | MP | C1188 C1391 C1714 | 1 | 0 |
substitute:
| Eye ointment 3 mg per g, 3.5 g | Application to the eye | Tobrex | AQ | MP | C1188 C1391 C1714 | 1 | 0 |
| AO | C1391 C1714 | 1 | 0 |
Schedule 1, entry for Trimethoprim with Sulfamethoxazole
omit:
| Tablet 80 mg-400 mg | Oral | Resprim | AF | PDP | 10 | 0 |
| Resprim | AF | MP NP | 10 | 1 |
Schedule 1, after entry for Zonisamide in the form Capsule 100 mg
insert:
| Zuclopenthixol Decanoate | Oily I.M. injection 200 mg in 1 mL | Injection | Clopixol Depot | LU | MP NP | 5 | 0 |
Schedule 3
omit:
| AW | Aspen Pharma Pty Ltd | 88 004 118 594 |
Schedule 3, after details relevant to Responsible Person code LN
insert:
| LO | LEO Pharma Pty Ltd | 72 147 880 617 |
Schedule 4, Part 1, entry for Calcipotriol with betamethasone
insert after existing text in the columns in the order indicated:
| C3827 | Chronic stable plaque type psoriasis vulgaris of the scalp in a patient who is not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy |
Schedule 4, Part 1, entry for Cetuximab
insert after existing text in the columns in the order indicated:
| C3843 | P3843 | Initial PBS-subsidised treatment, as monotherapy or in combination with an irinotecan based therapy, of a patient with a World Health Organisation performance status of 2 or less and with K-RAS wild type metastatic colorectal cancer after failure of first-line chemotherapy | Compliance with Authority Required procedures |
| C3844 | P3844 | Continuing PBS-subsidised treatment, as monotherapy or in combination with an irinotecan based therapy, of a patient with K-RAS wild type metastatic colorectal cancer who has previously been issued with an authority prescription for cetuximab and who does not have progressive disease | Compliance with Authority Required procedures |
Schedule 4, Part 1, entry for Ciprofloxacin
insert after existing text in the columns in the order indicated:
| C3830 | Bacterial keratitis under the supervision and direction of an ophthalmologist | Compliance with Authority Required procedures |
Schedule 4, omit entry for Clotrimazole
Schedule 4, Part 1, entry for Deferasirox
substitute:
| Deferasirox | C3828 | Where the patient is receiving treatment at/from a public hospital Chronic iron overload in patients with disorders of erythropoiesis | Compliance with Authority Required procedures - Streamlined Authority Code 3828 |
| C3829 | Where the patient is receiving treatment at/from a private hospital Chronic iron overload in patients with disorders of erythropoiesis | Compliance with Written or Telephone Authority Required procedures |
Schedule 4, Part 1, entry for Filgrastim
insert after existing text in the columns in the order indicated:
| C3833 | Where the patient is receiving treatment at/from a private hospital A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP) | Compliance with Written or Telephone Authority Required procedures |
| C3834 | Where the patient is receiving treatment at/from a public hospital A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP) | Compliance with Authority Required procedures - Streamlined Authority Code 3834 |
Schedule 4, Part 1, after entry for Filgrastim
insert:
| Fingolimod | C3845 | Initial treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in an ambulatory (without assistance or support) patient who has experienced at least 2 documented attacks of neurological dysfunction, believed to be due to the multiple sclerosis, in the preceding 2 years. The diagnosis must be confirmed by magnetic resonance imaging (MRI) of the brain and/or spinal cord and the date of the scan included in the authority application, unless the authority application is accompanied by written certification provided by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. The authority will be limited to the maximum quantity and number of repeats indicated in Schedule 1 | Compliance with Authority Required procedures |
| C3846 | Continuing treatment, as monotherapy, of clinically definite relapsing-remitting multiple sclerosis in a patient previously issued with an authority prescription for this drug who does not show continuing progression of disability while on treatment with this drug and who has demonstrated compliance with, and an ability to tolerate, this therapy. Authorities will be limited to the maximum quantity and number of repeats indicated in Schedule 1 | Compliance with Authority Required procedures |
Schedule 4, Part 1, entry for Fluconazole
insert after existing text in the columns in the order indicated:
| C3835 | Treatment of cryptococcal meningitis in a patient unable to take a solid dose form of fluconazole | Compliance with Authority Required procedures |
| C3836 | Maintenance therapy in a patient with cryptococcal meningitis and immunosuppression unable to take a solid dose form of fluconazole | Compliance with Authority Required procedures |
| C3837 | Treatment of oropharyngeal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole | Compliance with Authority Required procedures |
| C3838 | Treatment of oesophageal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole | Compliance with Authority Required procedures |
| C3839 | Prophylaxis of oropharyngeal candidiasis in an immunosuppressed patient unable to take a solid dose form of fluconazole | Compliance with Authority Required procedures |
| C3840 | Treatment of serious and life-threatening candida infections in a patient unable to take a solid dose form of fluconazole | Compliance with Authority Required procedures |
Schedule 4, Part 1, entry for Imatinib
omit:
| C3232 | P3232 | Gastrointestinal stromal tumour Continuing PBS-subsidised treatment, at a dose of up to 600 mg per day, of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour who have previously been issued with an authority prescription for this drug, and where the patient has not failed to respond, or is not intolerant, to imatinib | Compliance with Written or Telephone Authority Required procedures |
| C3451 | P3451 | Gastrointestinal stromal tumour Initial PBS-subsidised treatment, for up to 3 months, of adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining, where patients commence treatment at a dose that does not exceed 400 mg per day for at least 3 months, and where the application for authorisation includes a completed copy of the appropriate Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form which includes the following: (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and (ii) a copy of the most recent (within 2 months of the application) computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour or tumours, including whether or not there is evidence of metastatic disease; and (iii) where the application for authority to prescribe is being sought on the basis of an unresectable tumour, written evidence in support of that claim | Compliance with Written Authority Required procedures |
substitute:
| C3847 | P3847 | Resectable gastrointestinal stromal tumour Adjuvant treatment of a patient at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST) which has been histologically confirmed by the detection of CD117 on immunohistochemical staining, at a dose not exceeding 400 mg per day for a period of 12 months. High risk of recurrence is defined as: Primary GIST greater than 5 cm with a mitotic count of greater than 5/50 high power fields (HPF); or Primary GIST greater than 10 cm with any mitotic rate; or Primary GIST with a mitotic count of greater than 10/50 HPF. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form which includes the following: (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and (ii) a copy of the pathology report must include the size and mitotic rate of the tumour, and the date of tumour resection must be documented, which must not be more than 3 months prior to the date of this application | Compliance with Written Authority Required procedures |
| C3848 | P3848 | Resectable gastrointestinal stromal tumour Initial treatment of a patient who was receiving adjuvant imatinib mesylate for gastrointestinal stromal tumour (GIST) prior to 1 September 2011 and who meets the PBS eligibility criteria for adjuvant treatment with imatinib mesylate of a patient at high risk of recurrence following complete resection of primary GIST. The patient is eligible to receive sufficient imatinib at a dose of 400 mg per day to complete 12 months of combined PBS-subsidised and non-PBS-subsidised therapy. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form which includes the following: (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and (ii) a copy of the pathology report must include the size and mitotic rate of the tumour, and the date of tumour resection must be documented | Compliance with Written Authority Required procedures |
| C3849 | P3849 | Metastatic or unresectable gastrointestinal stromal tumour Initial PBS-subsidised treatment, for up to 3 months, of a patient with a metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining, where treatment is commenced at a dose that does not exceed 400 mg per day for at least 3 months, and where the application for authorisation is made in writing and includes a completed copy of the appropriate Imatinib Mesylate (Glivec) PBS Authority Application for Use in the Treatment of Metastatic or Unresectable Gastrointestinal Stromal Tumour - Supporting Information Form which includes the following: (i) a copy of a pathology report from an Approved Pathology Authority supporting the diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117 on immunohistochemical staining; and (ii) a copy of the most recent (within 2 months of the application) computed tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour or tumours, including whether or not there is evidence of metastatic disease; and (iii) where the application for authority to prescribe is being sought on the basis of an unresectable tumour, written evidence in support of that claim | Compliance with Written Authority Required procedures |
| C3850 | P3850 | Metastatic or unresectable gastrointestinal stromal tumour Continuing PBS-subsidised treatment, at a dose of up to 600 mg per day, of a patient with a metastatic or unresectable malignant gastrointestinal stromal tumour who has previously been issued with an authority prescription for this drug, and where the patient has not failed to respond, or is not intolerant, to imatinib | Compliance with Written or Telephone Authority Required procedures |
Schedule 4, Part 1, entry for Ofloxacin
insert after existing text in the columns in the order indicated:
| C3830 | Bacterial keratitis under the supervision and direction of an ophthalmologist. | Compliance with Authority Required procedures |
Schedule 4, Part 1, entry for Pegfilgrastim [Circumstances Code C2929]
omit text from column headed “Authority Required ─ Part of Circumstances” and substitute:
Compliance with Written or Telephone Authority Required procedures
Schedule 4, Part 1, entry for Pegfilgrastim [Circumstances Code C2930]
omit text from column headed “Authority Required ─ Part of Circumstances” and substitute:
Compliance with Written or Telephone Authority Required procedures
Schedule 4, Part 1, entry for Pegfilgrastim
insert after existing text in the columns in the order indicated:
| C3833 | Where the patient is receiving treatment at/from a private hospital A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP) | Compliance with Written or Telephone Authority Required procedures |
| C3834 | Where the patient is receiving treatment at/from a public hospital A patient being treated with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Hodgkin disease (first-line chemotherapy with escalated BEACOPP) | Compliance with Authority Required procedures - Streamlined Authority Code C3834 |
Schedule 4, Part 1, entry for Risperidone
insert after existing text in the columns in the order indicated:
| C3841 | Maintenance treatment, in combination with lithium or sodium valproate, of treatment refractory bipolar I disorder | Compliance with Authority Required procedures - Streamlined Authority Code C3841 |
Schedule 4, Part 1, omit entry for Sulindac
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0